Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$26.80
+1.1%
$23.38
$19.40
▼
$27.98
$13.39B1.735.54 million shs5.38 million shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$241.55
+0.5%
$229.13
$139.26
▼
$266.38
$15.50B0.38806,001 shs496,700 shs
Liquidia Corporation stock logo
LQDA
Liquidia
$57.41
-1.2%
$48.96
$22.31
▼
$93.61
$5.17B0.42.98 million shs1.93 million shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$167.40
-1.2%
$148.58
$122.14
▼
$186.12
$16.94B0.361.44 million shs1.38 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%+4.50%+13.97%+13.38%+21.64%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.00%+2.89%+12.65%-1.39%+76.69%
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+29.30%+65.07%-22.88%+102.79%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
0.00%+1.68%+22.23%+9.61%+13.99%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$26.80
+1.1%
$23.38
$19.40
▼
$27.98
$13.39B1.735.54 million shs5.38 million shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$241.55
+0.5%
$229.13
$139.26
▼
$266.38
$15.50B0.38806,001 shs496,700 shs
Liquidia Corporation stock logo
LQDA
Liquidia
$57.41
-1.2%
$48.96
$22.31
▼
$93.61
$5.17B0.42.98 million shs1.93 million shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$167.40
-1.2%
$148.58
$122.14
▼
$186.12
$16.94B0.361.44 million shs1.38 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%+4.50%+13.97%+13.38%+21.64%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.00%+2.89%+12.65%-1.39%+76.69%
Liquidia Corporation stock logo
LQDA
Liquidia
0.00%+29.30%+65.07%-22.88%+102.79%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
0.00%+1.68%+22.23%+9.61%+13.99%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$29.7511.01% Upside
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2.95
Moderate Buy$294.2521.82% Upside
Liquidia Corporation stock logo
LQDA
Liquidia
2.50
Moderate Buy$75.2331.04% Upside
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.88
Moderate Buy$202.5921.02% Upside

Current Analyst Ratings Breakdown

Latest LQDA, NBIX, JAZZ, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Boost Price TargetOverweight$319.00 ➝ $324.00
11/13/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Initiated CoverageBuy$76.00
11/13/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetEqual Weight$185.00 ➝ $191.00
11/12/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
DowngradeHold (C+) ➝ Hold (C-)
11/12/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Boost Price TargetOverweight$310.00 ➝ $330.00
11/12/2026
Liquidia Corporation stock logo
LQDA
Liquidia
UpgradeStrong Sell ➝ Hold
11/11/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Set Price TargetNeutral$54.00
11/11/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetEqual Weight$33.00 ➝ $40.00
11/11/2026
Liquidia Corporation stock logo
LQDA
Liquidia
UpgradeOutperform ➝ Strong-Buy$53.00 ➝ $77.00
11/11/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$58.00 ➝ $66.00
11/10/2026
Liquidia Corporation stock logo
LQDA
Liquidia
Boost Price TargetBuy$55.00 ➝ $62.00
(Data available from 11/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.84$2.35 per share11.42$13.26 per share2.02
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.27B3.63$16.34 per share14.78$65.30 per share3.70
Liquidia Corporation stock logo
LQDA
Liquidia
$621.87M8.32N/AN/A($0.28) per share-205.04
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.86B5.92$4.95 per share33.80$38.32 per share4.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.30N/A20.782.24-2.86%8.80%4.32%N/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-$356.15M$2.9482.1610.280.444.37%16.88%6.46%N/A
Liquidia Corporation stock logo
LQDA
Liquidia
-$68.92M-$1.23N/A14.531.39-15.15%264.65%44.19%N/A
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$478.60M$6.7424.8416.930.6918.98%23.39%16.22%N/A

Latest LQDA, NBIX, JAZZ, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Liquidia Corporation stock logo
LQDA
Liquidia
$0.96-$2.64-$3.60-$2.64$214.18 million$225.30 million
11/6/2026Q3 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.2028$0.27+$0.0672$0.04$1.21 billion$1.27 billion
11/2/2026Q3 2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-$4.03-$3.88+$0.15-$7.48$1.21 billion$1.24 billion
11/2/2026Q3 2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$1.91$3.29+$1.38$1.96$1.04 billion$1.12 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
Liquidia Corporation stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.55
2.09
1.10
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
1.09
1.82
1.64
Liquidia Corporation stock logo
LQDA
Liquidia
0.63
1.02
2.12
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
2.04
1.97

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
Liquidia Corporation stock logo
LQDA
Liquidia
64.54%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
92.59%

Insider Ownership

CompanyInsider Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
4.10%
Liquidia Corporation stock logo
LQDA
Liquidia
25.60%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.83 million494.13 millionOptionable
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2,89064.19 million61.56 millionOptionable
Liquidia Corporation stock logo
LQDA
Liquidia
21690.11 million67.04 millionOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2,000101.22 million96.56 millionOptionable

Recent News About These Companies

Neurocrine Updates Rare Epilepsy Study as NBI-921352 Trial Ends
Neurocrine Biosciences: Breaking Down A Solid Quarter

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$26.80 +0.30 (+1.13%)
Closing price 11/13/2026 03:59 PM Eastern
Extended Trading
$26.77 -0.03 (-0.10%)
As of 11/13/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$241.55 +1.18 (+0.49%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$241.51 -0.04 (-0.02%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Liquidia stock logo

Liquidia NASDAQ:LQDA

$57.41 -0.71 (-1.22%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$56.75 -0.66 (-1.14%)
As of 11/13/2026 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Neurocrine Biosciences stock logo

Neurocrine Biosciences NASDAQ:NBIX

$167.40 -2.00 (-1.18%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$163.34 -4.06 (-2.42%)
As of 11/13/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.